Mersana Therapeutics (MRSN) Files Mixed Shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Mersana (MRSN) PT Raised to $15 at Citi, Opens Catalyst Watch
May 10, 2023 3:24 PM EDTCiti analyst Ashiq Mubarack raised the price target on Mersana (NASDAQ: MRSN) to $15.00 (from $12.00) while maintaining a Buy rating.
The analys topens a 90-day upside catalyst watch commenting "In mid-2023, MRSN will share topline results from the pivotal UPLIFT Ph2 trial evaluating UpRi in... More
